JG
CBAY

Jefferies Group’s Cymabay Therapeutics CBAY Stock Holding History

Jefferies Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-84,488
Closed -$166K – 2785
2019
Q4 		$166K Buy
84,488
+69,433
+461% +$261K ﹤0.01% 2300
2019
Q3 		$77K Buy
+15,055
New +$91.1K ﹤0.01% 2545
2015
Q2 		– Sell
-21,646
Closed -$150K – 3544
2015
Q1 		$150K Buy
+21,646
New +$208K ﹤0.01% 1821

Other funds holding CBAY

ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Group's CBAY Position: Q1 2020 in Review

Jefferies Group sold out of Cymabay Therapeutics (CBAY) in Q1 2020, closing a stake of 84,488 shares — an estimated $166K sold.

Jefferies Group first reported a position in CBAY in Q1 2015 and held it in 3 quarters. The position peaked at $166K in Q4 2019. 102 funds tracked by Wall St. Rank hold CBAY as of Q1 2020.

  • Jefferies Group reported no remaining Cymabay Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Jefferies Group sold 84,488 Cymabay Therapeutics shares in Q1 2020, an estimated $166K.
  • Jefferies Group first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 3 quarters.
  • Jefferies Group's Cymabay Therapeutics position peaked at $166K in Q4 2019.
  • 102 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.